Preventing Organ Failure Through Early Detection

Delayed Treatment Costs Lives

Opticyte is transforming the standard of care for the leading causes of organ failure, including sepsis, with real-time measurement that is accurate for all skin tones.

The opportunity to save lives and improve patient care is global in scale with immense societal impact. There are 48.9 million sepsis cases and 11 million sepsis-related deaths as a result of organ failure worldwide each year. One person in the world dies every three seconds from organ failure related to sepsis, accounting for 20% of all deaths globally. Others survive only to endure prolonged periods of critical illness and dependency on vital organ support. The financial burden of treating sepsis costs the U.S. healthcare system alone nearly $25 billion dollars annually.*

Million sepsis cases worldwide each year
Million sepsis-related deaths worldwide each year

The Need is Now for Definitive, Actionable Oximetry Data

Every minute counts when a patient’s organs aren’t receiving enough oxygen. Today’s technology, including pulse oximeters, fails to provide clinicians with definitive, real-time information that can be used to prevent organ failure. Current methods for diagnosis rely on indirect indicators of cellular oxygen levels that are often too delayed, ambiguous or inaccurate – especially for darker skin tones – to help clinicians determine the correct dose and timing of treatment.

With Opticyte’s VitalO₂, clinicians can immediately respond to a patient’s urgent medical condition with confidence to prevent irreversible organ damage and failure.

Recognized by the FDA as a Breakthrough Device, the Opticyte VitalO₂ is the first device to measure oxygen levels inside cells in real time.

Organ failure results from prolonged, untreated low oxygen levels in cells due to sepsis, COVID-19, hemorrhage (blood loss), or cardiac failure. The US FDA awarded Opticyte’s VitalO₂ Breakthrough Device Designation for its potential to provide more effective treatment over the existing standard of care for identifying and treating life-threatening organ dysfunction.

“The Opticyte VitalO₂ has the potential for detecting mild to moderate shock during the ‘Golden Hour’ when the clinician still has the opportunity to reverse potentially fatal deterioration with current therapies.”

Robert Guthrie, MD, Drexel University

The World’s Only
Cellular Oxygen Monitor

Opticyte Render

The Opticyte VitalO₂ leverages proprietary advanced algorithms, tailored optical spectroscopy technology, and a functional, form-fitting disposable sensor to continuously measure oxygen levels inside cells in real time. The world’s first cellular oxygen monitor provides clinicians immediate, actionable insights related to organ oxygen deficiency caused by sepsis, internal bleeding, and other serious health conditions. Oxygen levels are measured where it matters most, inside cells – not just in the bloodstream like current pulse oximeters.

Health Equity: Addressing the Inaccuracy of Pulse Oximeters

During the COVID-19 pandemic, patients with darker skin died at a higher rate than patients with lighter skin, in part due to the inaccuracy of today’s pulse oximeters on darker skin patients. The FDA has launched an investigation into this issue and is seeking ways to address it. The Opticyte VitalO₂ uses full light spectra to accurately monitor blood and cell oxygenation for all patients, regardless of skin tone.

Join the Opticyte Solution

Learn How